Evaluation of Povidone-Iodine in Pleurodesis of Malignant Pleural Effusion

المؤلفون

  • Amhamed Ahmed Alhajaji Surgery department, Abuslem Trauma Center, Tripoli, Libya
  • Ali Giuma Elmarghni Surgery department, Abuslem Trauma Center, Tripoli, Libya

DOI:

https://doi.org/10.65540/jar.v24i.563

الكلمات المفتاحية:

pleurodesis، povidone-iodine، malignant pleural effusion

الملخص

Background: Malignant pleural effusion (MPE) is a condition that malignant cells are presented in the pleural fluid. 10% povidone-iodine in pleurodesis is one of (MPE) treatment options.

 This study aims  to evaluate the safety, efficacy and the success rate of 10% povidone-iodine in pleurodesis procedure through thoracostomy by conducting; the assessment of  radiological  and clinical outcome after using of povidone –iodine as a chemical pleurodesis agent.

Randomized clinical trial, was carried out on 18 cases  at Thoracic Surgery Department, Abuslem Trauma Center, Tripoli 2020 - 2021, all patients who underwent pleural drainge and received bedside mixture of 20 ml of 10% topical solution of povidone-iodine and 80 ml of normal saline, was Instilled into the pleural cavity through pleural catheter and then, the tube was clamped for 1 hour.

In the absence of excessive fluid drainage (> 250 mL/ day) and no fluid collection in chest x ray, the pleural catheter removed within 24-48 hours of sclerosant administration pleurodesis with 10% povidone-iodine.     After pleurodesis, all patients were assessed via chest X-ray (CXR) after procedure, and at one month.

Data collected throughout history, basic clinical examination, laboratory investigations and outcome measures coded, entered and analyzed using Microsoft Excel software.

Results: revealed that early response was 72.2% complete, partial in 16.6%, and failure 11.1%, major complication was nausea.

We concluded that povidone-iodine is a safe and effective agent with minor side effects in pleurodesis and treatment of MPE and proposed povidone-iodine as a proper, accessible, and low-cost alternative sclerosing agent.

المراجع

AeLony HY, King R and Boiitin C (1991): Thoracoscopic talc poudrage pleurodesis for chronic recurrent pleural effusions. Ann. Intern. Med; 115: 778-82. DOI: https://doi.org/10.7326/0003-4819-115-10-778

Agarwal, R; Khan, A; Aggarwal, AN; et al. (2012): Efficacy and safety of iodopovidone pleurodesis: a systematic review and meta-analysis. The Indian Journal of Medical Research; 135: 297–304.

Agostoni E, and Zocchi L (1998): Mechanical coupling and liquid exchanges in the pleural space. Clin Chest Med; 19 (2): 24l-261. DOI: https://doi.org/10.1016/S0272-5231(05)70075-7

Andrade-Neto JD, Oliveira SFQ, Vianna SP, et al. (2010): Efficacy and safety of iodopovidone pleurodesis in malignant pleural effusions. Respirology; 15: 115–118. DOI: https://doi.org/10.1111/j.1440-1843.2009.01663.x

Antony VB, Nasreen N, Mohammed KA, et al. (2004): Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis. Chest;126:1522-8. DOI: https://doi.org/10.1378/chest.126.5.1522

Antunes G, Neville E, Duffy J, Ali N (2003): BTS Guidelines for the management of malignant pleural effusions. Thorax; 58:ii29-ii38. DOI: https://doi.org/10.1136/thx.58.suppl_2.ii29

Arfa, M. A. (2014). Comparative study of pleurodesis using iodopovidone and bleomycin in management of malignant pleural effusion, (july).

Benkelman CJ, van den Berg AJ, Moekstra MJ, et al. (2008): Anti-inflammatory properties of a liposomal hydrogel with povidone-iodine (Repithel) for wound healing in vitro. Burns; 34: 845-855. DOI: https://doi.org/10.1016/j.burns.2007.11.014

Brega-Massone P, Conti B, Magnani B, et al. (2004): Minimally invasive thoracic surgery for diagnostic assessment and palliative treatment in recurrent neoplastic pleural effusion. Thorac Cardiovasc Surg; 52: 191–195. DOI: https://doi.org/10.1055/s-2004-820869

British Medical Association (2015): British national formulary: BNF; 69 (ed.): 840.

Broaddus VC (2008): Transudative pleural effusions. In: Loddenkemper R, Antony VB, ed. Pleural Diseases (European Respiratory Monograph, Vol 7, Monograph 22), Sheffield, UK: European Respiratory Society Journals: 157-176.

Bydder S, Phillips M, Joseph DJ, et al. (2004): A randomised trial of single-dose radiotherapy to prevent procedure tract metastasis by malignant mesothelioma. Br J Cancer; 91:9-10. DOI: https://doi.org/10.1038/sj.bjc.6601957

Caglayan B, Torun E, Turan D, et al. (2008): Efficacy of iodopovidone pleurodesis and comparison of small-bore catheter versus large-bore chest tube. Ann Surg Oncol; 15:2594-9. DOI: https://doi.org/10.1245/s10434-008-0004-1

Caldwell, J., Edriss, H., & Nugent, K. (2018, July). Chronic peritoneal indwelling catheters for the management of malignant and nonmalignant ascites. In Baylor University Medical Center Proceedings (Vol. 31, No. 3, pp. 297-302). Taylor & Francis. DOI: https://doi.org/10.1080/08998280.2018.1461525

Chakrabarti B, Ryland I, Sheard J, et al. (2006): The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions. Chest; 129(6): 1549-1555. DOI: https://doi.org/10.1378/chest.129.6.1549

Charpidou A., Harrington KJ, Syrigos KN (2006): Management of Malignant Pleural Effusions. In: Syrigos KS., Nutting CM, Roussos C. (eds.) Tumors of the Chest Biology, Diagnosis and Management. Berlin: Springer; 563-573. DOI: https://doi.org/10.1007/3-540-31040-1_49

Chen H, Brahmer J. Management of malignant pleural effusion. Curr Oncol Rep 2008;10:287-93. DOI: https://doi.org/10.1007/s11912-008-0045-4

Dias, J., Neto, A., Terra, M., Teixeira, M., Vianna, S., & Manuel, P. (2015). Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural Effusion, 225, 369–375. https://doi.org/10.1159/000440727. DOI: https://doi.org/10.1159/000440727

Dixit, R., Agarwal, K. C., Gokhroo, A., Patil, C. B., Meena, M., Shah, N. S., & Arora, P. (2017). Diagnosis and management options in malignant pleural effusions. Lung India: official organ of Indian Chest Society, 34(2), 160. DOI: https://doi.org/10.4103/0970-2113.201305

Dresler CM, Olak J, Herndon JE 2nd, et al. (2005): Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest; 127(3):909-15. DOI: https://doi.org/10.1378/chest.127.3.909

Dumville, JC; McFarlane, E; Edwards, P; et al. (2015): Preoperative skin antiseptics for preventing surgical wound infections after clean surgery. The Cochrane Database of Systematic Reviews; 4: CD003949. DOI: https://doi.org/10.1002/14651858.CD003949.pub4

Duysinx B, Nguyen D, Louis R, et al. (2004): Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest; 125:489-93. DOI: https://doi.org/10.1378/chest.125.2.489

Ellington MJ, Reuter S, Harris SR, et al. (2015): Emergent and evolving antimicrobial resistance cassettes in community-associated fusidic acid and meticillin-resistant Staphylococcus aureus. Int. J. Antimicrob. Agents; 45: 477-484. DOI: https://doi.org/10.1016/j.ijantimicag.2015.01.009

Garza-Gangemi, A. M., Barquet-Muñoz, S. A., Villarreal-Colín, S. P., Medina-Franco, H., Cortés-González, R., Vilar-Compte, D., & Cantú-de-León, D. (2016). Randomized Phase II Study of Talc Versus Iodopovidone for the Prevention of Seroma Formation Following Modified Radical Mastectomy. Revista de Investigación Clínica, 67(6), 357-365. DOI: https://doi.org/10.1016/S0034-8376(25)00259-1

التنزيلات

منشور

2023-03-31

كيفية الاقتباس

Alhajaji, A. A., & Elmarghni, A. G. (2023). Evaluation of Povidone-Iodine in Pleurodesis of Malignant Pleural Effusion. مجلة البحوث الأكاديمية, 24, 58–64. https://doi.org/10.65540/jar.v24i.563

إصدار

القسم

العلوم الهندسية والتطبيقية